Hostname: page-component-84b7d79bbc-5lx2p Total loading time: 0 Render date: 2024-07-26T07:23:52.943Z Has data issue: false hasContentIssue false
  • English
  • Français

Genomewide interaction and enrichment analysis on antidepressant response

Published online by Cambridge University Press:  01 July 2013

N. Antypa ,
A. Drago  and
A. Serretti
N. Antypa
Affiliation:
Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy
A. Drago
Affiliation:
IRCCS Centro S. Giovanni di Dio, Fatebenefratelli, Brescia, Italy
A. Serretti*
Affiliation:
Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy
*
*Address for correspondence: A. Serretti, M.D., Ph.D., Department of Biomedical and NeuroMotor Sciences, University of Bologna, Viale Carlo Pepoli 5, 40123 Bologna, Italy. (Email: alessandro.serretti@unibo.it)
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Genomewide association studies (GWASs) on antidepressant efficacy have yielded modest results. A possible reason is that response is influenced by other factors, which possibly interact with genetic variation. We used a GWAS model to predict antidepressant response, by including predictors previously known to affect response, such as quality of life (QoL). We also evaluated the association between genes, previously implicated in gene–environment (G × E) interactions, and response using an enrichment analysis.

Method

We examined a sample of 1426 depressed patients from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial: 774 responders, 652 non-responders and 418 865 single nucleotide polymorphisms (SNPs) were analysed. First, in a GWAS model, we investigated whether genetic variations interact with patients' levels of QoL to predict response, after controlling for demographic characteristics, severity and population stratification. Second, we conducted an enrichment analysis exploring whether candidate genes that have emerged from prior G × E interaction studies on depression are associated with treatment response.

Results

The GWAS model, with QoL as a moderator, yielded one SNP (rs520210) associated with response in the NEDD4L gene (p = 3.64 × 10−8). In the Caucasian sample only, we observed a drop in significance for this SNP. The enrichment analysis showed that SNPs within serotonergic genes contained more significant markers that predicted response, compared with a random set of genes in the genome.

Conclusions

Our findings point to possible target genes, which are proposed for further independent replication. Our enrichment analysis provides further support, in a genomewide context, of the role of serotonergic genes in influencing antidepressant response.

Keywords

Antidepressant responseenrichment analysisgenomewide interactionquality of life
Type
Original Articles
Information
Psychological Medicine , Volume 44 , Issue 4 , March 2014 , pp. 753 - 765
Copyright
Copyright © Cambridge University Press 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Anderson, CA, Pettersson, FH, Clarke, GM, Cardon, LR, Morris, AP, Zondervan, KT (2010). Data quality control in genetic case–control association studies. Nature Protocols 5, 1564–1573.Google Scholar
Appel, K, Schwahn, C, Mahler, J, Schulz, A, Spitzer, C, Fenske, K, Stender, J, Barnow, S, John, U, Teumer, A, Biffar, R, Nauck, M, Volzke, H, Freyberger, HJ, Grabe, HJ (2011). Moderation of adult depression by a polymorphism in the FKBP5 gene and childhood physical abuse in the general population. Neuropsychopharmacology 36, 1982–1991.Google Scholar
Araki, N, Umemura, M, Miyagi, Y, Yabana, M, Miki, Y, Tamura, K, Uchino, K, Aoki, R, Goshima, Y, Umemura, S, Ishigami, T (2008). Expression, transcription, and possible antagonistic interaction of the human Nedd4L gene variant: implications for essential hypertension. Hypertension 51, 773–777.Google Scholar
Baron, M (2002). Manic-depression genes and the new millennium: poised for discovery. Molecular Psychiatry 7, 342–358.Google Scholar
Binder, EB, Salyakina, D, Lichtner, P, Wochnik, GM, Ising, M, Putz, B, Papiol, S, Seaman, S, Lucae, S, Kohli, MA, Nickel, T, Kunzel, HE, Fuchs, B, Majer, M, Pfennig, A, Kern, N, Brunner, J, Modell, S, Baghai, T, Deiml, T, Zill, P, Bondy, B, Rupprecht, R, Messer, T, Kohnlein, O, Dabitz, H, Bruckl, T, Muller, N, Pfister, H, Lieb, R, Mueller, JC, Lohmussaar, E, Strom, TM, Bettecken, T, Meitinger, T, Uhr, M, Rein, T, Holsboer, F, Muller-Myhsok, B (2004). Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nature Genetics 36, 1319–1325.Google Scholar
Booij, L, Van der Does, W, Benkelfat, C, Bremner, JD, Cowen, PJ, Fava, M, Gillin, C, Leyton, M, Moore, P, Smith, KA, Van der Kloot, WA (2002). Predictors of mood response to acute tryptophan depletion. A reanalysis. Neuropsychopharmacology 27, 852–861.Google Scholar
Cohen, RM, Greenberg, JM, Ishak, WW (2013). Incorporating multidimensional patient-reported outcomes of symptom severity, functioning, and quality of life in the individual burden of illness index for depression to measure treatment impact and recovery in MDD. Journal of the American Medical Association Psychiatry 70, 343–350.Google Scholar
Cohen-Woods, S, Craig, IW, McGuffin, P (2013). The current state of play on the molecular genetics of depression. Psychological Medicine 43, 673–687.Google Scholar
Cornelis, MC, Tchetgen, EJ, Liang, L, Qi, L, Chatterjee, N, Hu, FB, Kraft, P (2012). Gene-environment interactions in genome-wide association studies: a comparative study of tests applied to empirical studies of type 2 diabetes. American Journal of Epidemiology 175, 191–202.Google Scholar
Daly, EJ, Trivedi, MH, Wisniewski, SR, Nierenberg, AA, Gaynes, BN, Warden, D, Morris, DW, Luther, JF, Farabaugh, A, Cook, I, Rush, AJ (2010). Health-related quality of life in depression: a STAR*D report. Annals of Clinical Psychiatry 22, 43–55.Google Scholar
Drago, A, De Ronchi, D, Serretti, A (2009). Pharmacogenetics of antidepressant response: an update. Human Genomics 3, 257–274.Google Scholar
Drago, A, Serretti, A (2011). Sociodemographic features predict antidepressant trajectories of response in diverse antidepressant pharmacotreatment environments: a comparison between the STAR*D study and an independent trial. Journal of Clinical Psychopharmacology 31, 345–348.Google Scholar
Endicott, J, Nee, J, Harrison, W, Blumenthal, R (1993). Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacology Bulletin 29, 321–326.Google Scholar
Fava, M, Rush, AJ, Trivedi, MH, Nierenberg, AA, Thase, ME, Sackeim, HA, Quitkin, FM, Wisniewski, S, Lavori, PW, Rosenbaum, JF, Kupfer, DJ (2003). Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Psychiatric Clinics of North America 26, 457–494.Google Scholar
Fishell, G, Hatten, ME (1991). Astrotactin provides a receptor system for CNS neuronal migration. Development 113, 755–765.Google Scholar
Flint, J, Munafo, MR (2013). Candidate and non-candidate genes in behavior genetics. Current Opinion in Neurobiology 23, 57–61.Google Scholar
Franchini, L, Serretti, A, Gasperini, M, Smeraldi, E (1998). Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. Journal of Psychiatric Research 32, 255–259.Google Scholar
Garriock, HA, Kraft, JB, Shyn, SI, Peters, EJ, Yokoyama, JS, Jenkins, GD, Reinalda, MS, Slager, SL, McGrath, PJ, Hamilton, SP (2010). A genomewide association study of citalopram response in major depressive disorder. Biological Psychiatry 67, 133–138.CrossRefGoogle ScholarPubMed
Ge, D, Zhang, K, Need, AC, Martin, O, Fellay, J, Urban, TJ, Telenti, A, Goldstein, DB (2008). WGAViewer: software for genomic annotation of whole genome association studies. Genome Research 18, 640–643.Google Scholar
Harding, MW, Galat, A, Uehling, DE, Schreiber, SL (1989). A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 341, 758–760.Google Scholar
Horstmann, S, Lucae, S, Menke, A, Hennings, JM, Ising, M, Roeske, D, Muller-Myhsok, B, Holsboer, F, Binder, EB (2010). Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 35, 727–740.Google Scholar
Ising, M, Lucae, S, Binder, EB, Bettecken, T, Uhr, M, Ripke, S, Kohli, MA, Hennings, JM, Horstmann, S, Kloiber, S, Menke, A, Bondy, B, Rupprecht, R, Domschke, K, Baune, BT, Arolt, V, Rush, AJ, Holsboer, F, Muller-Myhsok, B (2009). A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Archives of General Psychiatry 66, 966–975.Google Scholar
Karg, K, Sen, S (2012). Gene x environment interaction models in psychiatric genetics. Current Topics in Behavioral Neurosciences 12, 441–462.Google Scholar
Kato, M, Serretti, A (2010). Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Molecular Psychiatry 15, 473–500.Google Scholar
Keers, R, Uher, R (2012). Gene–environment interaction in major depression and antidepressant treatment response. Current Psychiatry Reports 14, 129–137.Google Scholar
Keers, R, Uher, R, Huezo-Diaz, P, Smith, R, Jaffee, S, Rietschel, M, Henigsberg, N, Kozel, D, Mors, O, Maier, W, Zobel, A, Hauser, J, Souery, D, Placentino, A, Larsen, ER, Dmitrzak-Weglarz, M, Gupta, B, Hoda, F, Craig, I, McGuffin, P, Farmer, AE, Aitchison, KJ (2011). Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. Pharmacogenomics Journal 11, 138–145.Google Scholar
Khoury, MJ, Wacholder, S (2009). Invited commentary: from genome-wide association studies to gene–environment-wide interaction studies – challenges and opportunities. American Journal of Epidemiology 169, 227–230.Google Scholar
Kirchheiner, J, Lorch, R, Lebedeva, E, Seeringer, A, Roots, I, Sasse, J, Brockmöller, J (2008). Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics 9, 841–846.Google Scholar
Kishi, T, Yoshimura, R, Kitajima, T, Okochi, T, Okumura, T, Tsunoka, T, Yamanouchi, Y, Kinoshita, Y, Kawashima, K, Naitoh, H, Nakamura, J, Ozaki, N, Iwata, N (2010). HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort. Neuromolecular Medicine 12, 237–242.Google Scholar
Koo, JW, Russo, SJ, Ferguson, D, Nestler, EJ, Duman, RS (2010). Nuclear factor-κB is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proceedings of the National Academy of Sciences USA 107, 2669–2674.CrossRefGoogle ScholarPubMed
Kristjansson, K, Manolescu, A, Kristinsson, A, Hardarson, T, Knudsen, H, Ingason, S, Thorleifsson, G, Frigge, ML, Kong, A, Gulcher, JR, Stefansson, K (2002). Linkage of essential hypertension to chromosome 18q. Hypertension 39, 1044–1049.Google Scholar
Laje, G, Perlis, RH, Rush, AJ, McMahon, FJ (2009). Pharmacogenetics studies in STAR*D: strengths, limitations, and results. Psychiatric Services 60, 1446–1457.Google Scholar
LaPlant, Q, Chakravarty, S, Vialou, V, Mukherjee, S, Koo, JW, Kalahasti, G, Bradbury, KR, Taylor, SV, Maze, I, Kumar, A, Graham, A, Birnbaum, SG, Krishnan, V, Truong, HT, Neve, RL, Nestler, EJ, Russo, SJ (2009). Role of nuclear factor κB in ovarian hormone-mediated stress hypersensitivity in female mice. Biological Psychiatry 65, 874–880.Google Scholar
Lekman, M, Laje, G, Charney, D, Rush, AJ, Wilson, AF, Sorant, AJ, Lipsky, R, Wisniewski, SR, Manji, H, McMahon, FJ, Paddock, S (2008). The FKBP5-gene in depression and treatment response – an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) cohort. Biological Psychiatry 63, 1103–1110.Google Scholar
Licht, CM, de Geus, EJ, Seldenrijk, A, van Hout, HP, Zitman, FG, van Dyck, R, Penninx, BW (2009). Depression is associated with decreased blood pressure, but antidepressant use increases the risk for hypertension. Hypertension 53, 631–638.Google Scholar
Lucae, S, Ising, M, Horstmann, S, Baune, BT, Arolt, V, Muller-Myhsok, B, Holsboer, F, Domschke, K (2010). HTR2A gene variation is involved in antidepressant treatment response. European Neuropsychopharmacology 20, 65–68.CrossRefGoogle ScholarPubMed
Malhotra, AK (2010). The pharmacogenetics of depression: enter the GWAS. American Journal of Psychiatry 167, 493–495.Google Scholar
Mandelli, L, Marino, E, Pirovano, A, Calati, R, Zanardi, R, Colombo, C, Serretti, A (2009). Interaction between SERTPR and stressful life events on response to antidepressant treatment. European Neuropsychopharmacology 19, 64–67.Google Scholar
McMahon, FJ, Buervenich, S, Charney, D, Lipsky, R, Rush, AJ, Wilson, AF, Sorant, AJ, Papanicolaou, GJ, Laje, G, Fava, M, Trivedi, MH, Wisniewski, SR, Manji, H (2006). Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. American Journal of Human Genetics 78, 804–814.Google Scholar
Murcray, CE, Lewinger, JP, Conti, DV, Thomas, DC, Gauderman, WJ (2011). Sample size requirements to detect gene–environment interactions in genome-wide association studies. Genetic Epidemiology 35, 201–210.Google Scholar
Nwulia, EA, Miao, K, Zandi, PP, Mackinnon, DF, DePaulo, JR Jr, McInnis, MG (2007). Genome-wide scan of bipolar II disorder. Bipolar Disorders 9, 580–588.Google Scholar
O'Reilly, RL, Bogue, L, Singh, SM (1994). Pharmacogenetic response to antidepressants in a multicase family with affective disorder. Biological Psychiatry 36, 467–471.Google Scholar
Paddock, S, Laje, G, Charney, D, Rush, AJ, Wilson, AF, Sorant, AJ, Lipsky, R, Wisniewski, SR, Manji, H, McMahon, FJ (2007). Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. American Journal of Psychiatry 164, 1181–1188.Google Scholar
Papakostas, GI, Fava, M (2008). Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder. Dialogues in Clinical Neuroscience 10, 439–451.CrossRefGoogle ScholarPubMed
Papakostas, GI, Fava, M (2009). Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. European Neuropsychopharmacology 19, 34–40.Google Scholar
Phipson, B, Smyth, GK (2010). Permutation P-values should never be zero: calculating exact P-values when permutations are randomly drawn. Statistical Applications in Genetics and Molecular Biology 9, 39.Google Scholar
Porcelli, S, Drago, A, Fabbri, C, Gibiino, S, Calati, R, Serretti, A (2011). Pharmacogenetics of antidepressant response. Journal of Psychiatry and Neuroscience 36, 87–113.Google Scholar
Price, AL, Patterson, NJ, Plenge, RM, Weinblatt, ME, Shadick, NA, Reich, D (2006). Principal components analysis corrects for stratification in genome-wide association studies. Nature Genetics 38, 904–909.Google Scholar
Purcell, S, Neale, B, Todd-Brown, K, Thomas, L, Ferreira, MA, Bender, D, Maller, J, Sklar, P, de Bakker, PI, Daly, MJ, Sham, PC (2007). PLINK: a tool set for whole-genome association and population-based linkage analyses. American Journal of Human Genetics 81, 559–575.Google Scholar
Pyne, JM, Bullock, D, Kaplan, RM, Smith, TL, Gillin, JC, Golshan, S, Kelsoe, JR, Williams, DK (2001). Health-related quality-of-life measure enhances acute treatment response prediction in depressed inpatients. Journal of Clinical Psychiatry 62, 261–268.Google Scholar
Ritsner, M, Kurs, R, Gibel, A, Ratner, Y, Endicott, J (2005). Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients. Quality of Life Research 14, 1693–1703.Google Scholar
Rush, AJ, Trivedi, M, Fava, M (2003). Depression, IV: STAR*D treatment trial for depression. American Journal of Psychiatry 160, 237.Google Scholar
Serretti, A, Benedetti, F, Zanardi, R, Smeraldi, E (2005). The influence of serotonin transporter promoter polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments. Progress in Neuro-psychopharmacology and Biological Psychiatry 29, 1074–1084.Google Scholar
Siddiqui, NU, Li, X, Luo, H, Karaiskakis, A, Hou, H, Kislinger, T, Westwood, JT, Morris, Q, Lipshitz, HD (2012). Genome-wide analysis of the maternal-to-zygotic transition in Drosophila primordial germ cells. Genome Biology 13, R11.Google Scholar
Souery, D, Oswald, P, Massat, I, Bailer, U, Bollen, J, Demyttenaere, K, Kasper, S, Lecrubier, Y, Montgomery, S, Serretti, A, Zohar, J, Mendlewicz, J (2007). Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. Journal of Clinical Psychiatry 68, 1062–1070.Google Scholar
Svensson-Färbom, P, Wahlstrand, B, Almgren, P, Dahlberg, J, Fava, C, Kjeldsen, S, Hedner, T, Melander, O (2011). A functional variant of the NEDD4L gene is associated with beneficial treatment response with β-blockers and diuretics in hypertensive patients. Journal of Hypertension 29, 388–395.Google Scholar
Trivedi, MH, Rush, AJ, Wisniewski, SR, Nierenberg, AA, Warden, D, Ritz, L, Norquist, G, Howland, RH, Lebowitz, B, McGrath, PJ, Shores-Wilson, K, Biggs, MM, Balasubramani, GK, Fava, M (2006 a). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. American Journal of Psychiatry 163, 28–40.Google Scholar
Trivedi, MH, Rush, AJ, Wisniewski, SR, Warden, D, McKinney, W, Downing, M, Berman, SR, Farabaugh, A, Luther, JF, Nierenberg, AA, Callan, JA, Sackeim, HA (2006 b). Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D report. Journal of Clinical Psychiatry 67, 185–195.Google Scholar
Uher, R (2011). Genes, environment, and individual differences in responding to treatment for depression. Harvard Review of Psychiatry 19, 109–124.Google Scholar
Uher, R, Huezo-Diaz, P, Perroud, N, Smith, R, Rietschel, M, Mors, O, Hauser, J, Maier, W, Kozel, D, Henigsberg, N, Barreto, M, Placentino, A, Dernovsek, MZ, Schulze, TG, Kalember, P, Zobel, A, Czerski, PM, Larsen, ER, Souery, D, Giovannini, C, Gray, JM, Lewis, CM, Farmer, A, Aitchison, KJ, McGuffin, P, Craig, I (2009). Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics Journal 9, 225–233.Google Scholar
Uher, R, McGuffin, P (2010). The moderation by the serotonin transporter gene of environmental adversity in the etiology of depression: 2009 update. Molecular Psychiatry 15, 18–22.Google Scholar
Uher, R, Perroud, N, Ng, MY, Hauser, J, Henigsberg, N, Maier, W, Mors, O, Placentino, A, Rietschel, M, Souery, D, Zagar, T, Czerski, PM, Jerman, B, Larsen, ER, Schulze, TG, Zobel, A, Cohen-Woods, S, Pirlo, K, Butler, AW, Muglia, P, Barnes, MR, Lathrop, M, Farmer, A, Breen, G, Aitchison, KJ, Craig, I, Lewis, CM, McGuffin, P (2010). Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. American Journal of Psychiatry 167, 555–564.Google Scholar
Weiss, LA, Arking, DE, Daly, MJ, Chakravarti, A (2009). A genome-wide linkage and association scan reveals novel loci for autism. Nature 461, 802–808.Google Scholar
Wilson, PM, Fryer, RH, Fang, Y, Hatten, ME (2010). Astn2, a novel member of the astrotactin gene family, regulates the trafficking of ASTN1 during glial-guided neuronal migration. Journal of Neuroscience 30, 8529–8540.Google Scholar
Wong, ML, Dong, C, Andreev, V, Arcos-Burgos, M, Licinio, J (2012). Prediction of susceptibility to major depression by a model of interactions of multiple functional genetic variants and environmental factors. Molecular Psychiatry 17, 624–633.Google Scholar
Zheng, C, Heintz, N, Hatten, ME (1996). CNS gene encoding astrotactin, which supports neuronal migration along glial fibers. Science 272, 417–419.Google Scholar
Zimmermann, P, Bruckl, T, Nocon, A, Pfister, H, Binder, EB, Uhr, M, Lieb, R, Moffitt, TE, Caspi, A, Holsboer, F, Ising, M (2011). Interaction of FKBP5 gene variants and adverse life events in predicting depression onset: results from a 10-year prospective community study. American Journal of Psychiatry 168, 1107–1116.Google Scholar
Supplementary material: File

Anytpa Supplementary Material

Appendix

Download Anytpa Supplementary Material(File)
File 333.8 KB